CERID Circles_Grey-03.png

Pre-Exposure Prophylaxis (PrEP) HIV Study


Principle Investigator: Bailey Bolton


The Pre-exposure prophylaxis study ​is a retrospective medical record view of all patients attending the University of Louisville Division of Infectious Diseases 550 clinic for HIV pre-exposure prophylaxis. The study is led by Dr. Bailey Bolten. The PrEP study aims to determine the characteristics, risk factors, outcomes, and affordability of obtaining PrEP for the enrolled patients for HIV prevention. The secondary objective is to describe and analyze the clinical management of patients using PrEP at this clinic.

HIV Pre-exposure prophylaxis (PrEP) is a combination of anti-retroviral medication taken once a day. PrEP is intended for people who are HIV-negative and are at high risk of contracting HIV.  In 2016, there were nearly 40,000 new diagnosis of HIV in the United States.  Jefferson County's HIV incidence for 2016 was 22.4 per 100,000 people, the highest in Kentucky. In the fall of 2017, as part of the patient available services, the University of Louisville, Division of Infectious Diseases, Outpatient Clinic (550 Clinic) started providing PrEP consultation and management.